Globus Pharmachem (Para Products Pvt Ltd)

Main products: Nimesulide,Chlorzoxazone,Aceclofenac,Paracetamol,Diclofenac epolamine

Current Location: HOME >> About Us
Contact Supplier
Globus Pharmachem (Para Products Pvt Ltd)
Country: India
Tel: +911204198900
Mobile: 9899370547
E-mail: info@globuspharmachem.com
WhatsApp: Chat Now!
Skype: Chat Now!

The genesis of Globus lies in Goyal Group of Industries founded by Lt Shri P.D.Goyal in 1975 with chemicals and dyes intermediates as its main products progressing to pharmaceuticals in 1995.

Our DNA strands have evolved into several well defined product lines covering Pharmaceuticals, Dyes Intermediates, Beuzine Derivatives, Industrial Chemicals and Plasticizers


Globus is the umbrella group with a number of associated sister concerns each manufacturing a distinct product line.  Our group companies include:
• Sara Exports Ltd, Ghaziabad
• Para Products Pvt Ltd, Ghaziabad
• Meditech Chemicals Pvt Ltd, Ghaziabad
• Dauxil Products, Jodhpur

Besides, we have two more Sister Concerns namely:
• Kutch Chemicals India Ltd., Gujarat
• Panoli Intermediates India Pvt Ltd, Gujarat

Rooted in Gujarat where we have a number of manufacturing units, we set up additional state of art manufacturing facilities for pharmaceutical intermediates and API products at the Mega Industrial Estate at Ghaziabad (UP) near New Delhi.

Globus Group is family owned and operated but follows enlightened modern management practices and a professional approach to doing business in the current context.

Our accent is on making best in class products at prices substantially lower than those prevailing worldwide, a feature that has gained us entry into export markets of South East Asia, Middle East and North Africa.

Our prime clients in India and in other countries are from the pharmaceuticals, chemicals, agro-chemicals, plasticizers and pesticides segment.  Our specialty is consistency, prompt deliveries, excellent customer relationship and fair prices.

Never content with remaining static, Globus is always expanding horizontally and vertically and we have ambitious plans for the future starting with antibiotic drug (API) to our product portfolio and adding on more anti-inflammatory drugs to the existing range so as to become leader in the anti-inflammatory category.